Project description
Two novel Notch pathway inhibitors as an antitumour therapeutics
The self-renewal of multipotent cancer stem cells (CSC) strongly correlates with tumour resistance associated with tumour heterogeneity. The evolutionarily conserved Notch signalling pathway is involved in cell-cell communication and controls multiple cell differentiation processes during embryonic and adult life. The Notch CSC signalling pathway is frequently deregulated in human cancers. The EU-funded INGSIGHT project will assess the technical and commercial feasibility of two novel inhibitors of the Notch pathway with the potential to radically improve cancer therapy outcomes. The study will demonstrate the maximum tolerated dose in normal tissues, the therapeutic effects using tumour models, and will conduct market analysis to ensure the selection of the optimal business strategy.
Fields of science
Call for proposal
ERC-2020-PoC
See other projects for this call
Funding Scheme
ERC-POC-LS - ERC Proof of Concept Lump Sum PilotHost institution
6200 MD Maastricht
Netherlands
Beneficiaries (1)
6200 MD Maastricht